Identification of potential therapeutic dual inhibitors of EGFR/HER2 in breast cancer

Identification of potential therapeutic dual inhibitors of EGFR/HER2 in breast cancer

Breast cancer (BC) is the leading cause of death among women worldwide. According to the Breast Cancer Research Foundation (BCRF), 25% of all cases of BC are positive for human epidermal growth factor receptor 2 (HER2), which is the most aggressive phenotype among the five BC subtypes. Previous stud...

Full description

Bibliographic Details
Main Authors:	Megha Jethwa, Aditi Gangopadhyay, Achintya Saha
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Series:	European Journal of Medicinal Chemistry Reports
Subjects:	Dual inhibitor EGFR HER2 Pharmacophore model Docking Molecular dynamics simulation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772417424000153

Similar Items

Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2
by: Frangky Sangande, et al.
Published: (2020-10-01)

Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2
by: Irving Balbuena-Rebolledo, et al.
Published: (2021-08-01)

Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors
by: Lianbao Ye, et al.
Published: (2019-01-01)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
by: Lisandra Negrón-Vega, et al.
Published: (2022-09-01)

Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth
by: Chia-Wei Weng, et al.
Published: (2022-03-01)

EGFR Expression in HER2-Driven Breast Cancer Cells
by: Florian Weinberg, et al.
Published: (2020-11-01)

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
by: Esraa A. Abdelsalam, et al.
Published: (2022-12-01)

Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors
by: Mostafa M. Ghorab, et al.
Published: (2018-01-01)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
by: Andrew T Baker, et al.
Published: (2014-12-01)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
by: Diana B. Peckys, et al.
Published: (2021-11-01)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
by: Kimio Yonesaka
Published: (2021-03-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme
by: Tenzin Adon, et al.
Published: (2023-03-01)

Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer
by: Ayed A. Dera, et al.
Published: (2023-06-01)

Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors
by: Kenny Chitcholtan, et al.
Published: (2020-03-01)

Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
by: Raghuveer Kavarthapu, et al.
Published: (2021-09-01)

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
by: Yohei Harada, et al.
Published: (2023-01-01)

Diosgenin and Monohydroxy Spirostanol from <i>Prunus amygdalus var amara</i> Seeds as Potential Suppressors of EGFR and HER2 Tyrosine Kinases: A Computational Approach
by: Mohammed Helmy Faris Shalayel, et al.
Published: (2023-05-01)

The potential of panHER inhibition in cancer
by: Xiaochun eWang, et al.
Published: (2015-01-01)

New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
by: Mariam M. Fakhry, et al.
Published: (2023-11-01)

Dual Targeting of EZH2 Degradation and EGFR/HER2 Inhibition for Enhanced Efficacy against Burkitt’s Lymphoma
by: Se Been Kim, et al.
Published: (2023-09-01)

Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors
by: Tarek S. Ibrahim, et al.
Published: (2021-11-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Synthesis and Antiproliferative Potential of Thiazole and 4-Thiazolidinone Containing Motifs as Dual Inhibitors of EGFR and BRAF<sup>V600E</sup>
by: Alaa A. Hassan, et al.
Published: (2023-12-01)

Synthesis, anticancer activity and docking studies of pyrazoline and pyrimidine derivatives as potential epidermal growth factor receptor (EGFR) inhibitors
by: Menier Al-Anazi, et al.
Published: (2022-07-01)

A multifaceted approach for the development of novel Hantzsch 1,4-dihydropyridines as anticancer agents: Rational design, parallel synthesis, analysis, cytotoxicity and EGFR/HER2 inhibition studies
by: A.S.V.L. Sruthi, et al.
Published: (2024-01-01)

Virtual Screening for Potential Allosteric Inhibitors of Cyclin-Dependent Kinase 2 from Traditional Chinese Medicine
by: Fang Lu, et al.
Published: (2016-09-01)

Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for Breast Cancer Patients
by: Shayalini Wignarajah, et al.
Published: (2023-03-01)

Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer
by: Sabrina A. Maisel, et al.
Published: (2019-06-01)

Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
by: Nina Shaban, et al.
Published: (2023-12-01)

Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways
by: Hyuk Moon, et al.
Published: (2022-04-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization
by: Mohamed F. Zayed, et al.
Published: (2018-07-01)

EGFR and HER2neu Expression in Gall Bladder Carcinoma and Its Association with Clinicopathological Parameters - An Institutional Experience from North India
by: Inara Abeer, et al.
Published: (2021-03-01)

Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages
by: Daeun You, et al.
Published: (2023-01-01)

Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 <i>Diabetes Mellitus</i> Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and <i>De Novo</i> Evolution
by: Azizullo Musoev, et al.
Published: (2019-08-01)

Discovery of Potent Dual EGFR/HER2 Inhibitors Based on Thiophene Scaffold Targeting H1299 Lung Cancer Cell Line
by: Ranza Elrayess, et al.
Published: (2020-12-01)